In the face of pandemic-era recruitment barriers and aggressive timelines, CRC partnered with a sponsor developing a novel Alzheimer’s treatment to support three early-phase trials—advancing the program from first-in-human (FIH) to long-term safety evaluation.
Across all three studies, CRC delivered consistent communication, high-touch site engagement, and trusted operational oversight to keep the program moving forward:
- Trial A: Phase I FIH study in healthy volunteers (47 subjects, 1 site)
- Trial B: Phase Ib/IIa study in Alzheimer’s patients (158 subjects, 18 sites)
- Trial C: Phase II OLE in rollover and de novo patients (121 subjects, 13 sites)
Despite compressed SAD/MAD timelines, turnover among vendor staff, and participant hesitations during COVID-19, CRC ensured on-time and on-budget completion—positioning the sponsor to move confidently into the next phase of development.
